Prognosis
First DNA Covid Vaccine Found 67% Effective in Clinical Trials
- Cadila Healthcare is seeking approval from India’s regulator
- Company says trial demonstrated efficacy against variant
Photographer: Akos Stiller/Bloomberg
This article is for subscribers only.
India’s Cadila Healthcare Ltd. has sought approval from the local drug regulator for its DNA-based vaccine against Covid-19 after the shot proved effective in clinical trials.
The drugmaker applied for emergency use authorization for the shot, which uses DNA to instruct the body’s cells to produce proteins that spark a protective response, according to an exchange filing Thursday. The Phase 3 trials on more than 28,000 volunteers across 50 centers showed an efficacy rate of 67%, Cadila said. That is below the rates of the shots from Moderna Inc. and Pfizer-BioNTech that use messenger RNA technology.